No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
BINEX Co., Ltd. operates as a pharmaceutical enterprise based in South Korea. The company provides an extensive array of medicinal products, encompassing bisroot items, gastrointestinal treatments (including antispasmodics and antiulcerants), NSAIDs, cardiovascular and urology medications, hepatic protective agents, topical ointments and creams, ophthalmic solutions, CNS agents, digestive aids, remedies for constipation and circulation, antibiotics and antifungals, cough and cold preparations, vitamins and nutritional supplements, antihistamines, antivertigo agents, and over-the-counter (OTC) drugs. Additionally, BINEX Co., Ltd. maintains a co-development alliance with Genexine, Inc. focused on the creation of a COVID-19 vaccine. Founded in 1957, its headquarters are situated in Incheon, South Korea.
www.bi-nex.comNo one on the platform currently holds 053030.KQ.
No tracked institution reports a position in 053030.KQ as of their last filing.
No one on the platform has traded 053030.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 29.5% | 4.8% | ||||
| Profit Margin % | -1.9% | -0.7% | -0.4% | |||
| Free Cash Flow Margin % | -26.4% | -11.5% | -3.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $184.0B | +1.9% | $-87.08 | $-90.56–$-83.60 | — | 2 |
| 2027 | $219.1B | +19.1% | $206.86 | $55.50–$358.22 | — | 2 |
| 2028 | $254.6B | +16.2% | $469.35 | $461.84–$476.85 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $7.93 | $7.21 | -9.1% |
| 2026-05-15 | $-105.19 | $-294.33 | -179.8% |
| 2026-03-04 | $20.12 | $-112.59 | -659.6% |
| 2025-11-14 | $86.76 | $-29.37 | -133.9% |
| 2025-08-14 | $86.76 | $44.10 | -49.2% |
| 2025-05-14 | $41.87 | $0.39 | -99.1% |
| 2025-03-14 | $17.57 | $-256.04 | -1557.3% |
| 2024-11-15 | $-148.29 | $-382.00 | -157.6% |
| $9860.00 |
| +3.79% |
| $254.5B |
| — |
| 078160.KQMEDIPOST Co., Ltd. | $8700.00 | +0.00% | $340.0B | — |
| 099190.KQi-SENS, Inc. | $16260.00 | +0.00% | $465.8B | — |
Source: Financial Modeling Prep · peers by sector/industry